Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

56.29USD
16 Feb 2018
Change (% chg)

$0.30 (+0.54%)
Prev Close
$55.99
Open
$55.99
Day's High
$56.98
Day's Low
$55.99
Volume
4,107,505
Avg. Vol
3,973,811
52-wk High
$66.80
52-wk Low
$53.36

Select another date:

Sat, Feb 17 2018

Photo

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

UPDATE 1-Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1

* SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1

BRIEF-Nestle declines to comment on interest in Pfizer, Merck units

* CEO SAYS NO COMMENT ON INTEREST IN PFIZER, MERCK CONSUMER HEALTH UNITS, BUT IS GENERALLY INTERESTED IN EXPANDING ITS CONSUMER HEALTH BUSINESS

Merck scraps another late-stage Alzheimer's drug study

NEW YORK Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer's drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease.

Merck scraps another late-stage Alzheimer's drug study

NEW YORK, Feb 13 Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer's drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease.

BRIEF-Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat For The Treatment Of People With Prodromal Alzheimer’S Disease

* MERCK ANNOUNCES DISCONTINUATION OF APECS STUDY EVALUATING VERUBECESTAT (MK-8931) FOR THE TREATMENT OF PEOPLE WITH PRODROMAL ALZHEIMER’S DISEASE

Appeals court ends Merck patent challenge to Amneal's generic Nasonex

A federal appeals court on Friday upheld a patent ruling that allowed generic drug maker Amneal Pharmaceuticals LLC to launch a low-cost version of Merck & Co Inc's nasal spray Nasonex.

Bristol-Myers' positive cancer data still lags Merck

Bristol-Myers Squibb Co on Monday provided some positive data on its immuno-oncology drugs for the most lucrative lung cancer market but it fell short of giving clarity on its ability to compete with a rival treatment from Merck & Co Inc

Select another date: